SSSteven S. Shen

Steven S. Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven S. Shen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Jae Y. Ro

    4 shared publications
  • Luan D. Truong

    3 shared publications
  • Alberto G. Ayala

    2 shared publications
  • Jijiang Zhu

    From the Department of Pathology, The Methodist Hospital and Research Institute, Weill Medical College of Cornell University, Houston, Tex (Drs Shen and Ro); and the Departments of Pathology (Drs Haupt, Zhu, and Schwartz) and the Division of Colon and Rectal Surgery, Department of Surgery (Dr Bailey), The Methodist Hospital, Houston, Tex

    2 shared publications
  • Alberto G Ayala

    Department of Pathology, The Methodist Hospital and Research Institute, Weill Medical College of Cornell University Houston, TX 77030

    1 shared publication
  • Antonio Lopez-Beltran

    Department of Pathology, Cordoba University Medical School, Cordoba, Spain

    1 shared publication

Latest Publications

  • Use of frozen section in genitourinary pathology

    by Steven S. Shen, Luan D. Truong, Jae Y. Ro, Alberto G. Ayala


  • Role of Immunohistochemistry in Diagnosing Renal Neoplasms: When Is It Really Useful?

    by Steven S. Shen, Luan D. Truong, Marina Scarpelli, Antonio Lopez-Beltran

    Context.—With the refinement of molecular and histologic classifications of renal neoplasms and the availability of more-effective molecular targeted therapy for specific renal neoplasms, immunohistochemical techniques will play an increasingly important role in the diagnosis of renal neoplasm. During the past few decades, many markers have been evaluated for their role in the diagnosis, prognosis, and prediction of treatment for renal neoplasms. The number of useful markers in our routine practice continues to increase. The challenge will be to choose among them and to decide in which situations immunohistochemistry will be truly useful. Objectives.—To review the diagnostic utility of molecular markers for renal neoplasms and common diagnostic scenarios that call for immunohistochemistry in routine practice. Data Sources.—This review is based on published literature and personal experience. Conclusions.—Some of the most important and useful markers for the diagnosis of renal neoplasm include cytokeratins, vimentin, PAX2, PAX8, RCC marker, CD10, E-cadherin, kidney-specific cadherin, parvalbumin, claudin-7, claudin-8, α-methylacyl coenzyme A racemase, CD117, TFE3, thrombomodulin, uroplakin III, p63, CD57, and carbonic anhydrase IX. Each marker has its diagnostic role in a specific diagnostic setting. The common diagnostic situations that call for immunohistochemical staining are differential diagnoses of renal versus nonrenal neoplasms, histologic subtyping of renal cell carcinoma, diagnosis of rare primary renal neoplasms, diagnosis of renal neoplasms in small core-biopsy specimens, diagnosis of possible metastatic renal carcinomas, and less frequently, molecular prognostication.


  • Carcinoma of müllerian origin presenting as colorectal cancer: a clinicopathologic study of 13 Cases

    by Qin Yang, Huamin Wang, Hyun Y. Cho, Soo Jin Jung, Kyu-Rae Kim, Jae Y. Ro, Steven S. Shen


  • Mucinous Tubular and Spindle Cell Carcinoma of Kidney

    by Harin Cheong, Jae Y. Ro, Federico A. Monzon, Alberto G. Ayala, Steven S. Shen

    Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare morphologic variant of renal cell carcinoma (RCC) characterized by an epithelial-tubular proliferation admixed with spindle cell areas and a myxoid or mucinous stroma. It was initially referred as an unusual renal carcinoma with prominent spindle cell change, RCC with loop of Henle differentiation, low-grade myxoid tumor, and low grade collecting duct carcinoma.1–6 In 2004, it has been recognized as a distinct entity of RCC in the 2004 World Health Organization tumor classification.7,8 Since then, several dozen of MTSCCs have been reported with additional complementary morphologic features, immunohistochemical profiles, and cytogenetic changes that have further clarified its clinicopathologic features. 9–14 It was initially thought to be a “low-grade” renal cell tumor because of its bland nuclear features and indolent behavior. However, it has became clear that MTSCC has a histological spectrum ranging from low to high grade that includes, rarely, sarcomatoid differentiation. In addition to nodal metastasis, distant metastasis and death of patients have been described.15–17 Herein, we present a case of MTSCC and summarize the current knowledge regarding histological and immunohistochemical features, differential diagnosis, and prognostic factors.

  • Open Access

    Expression of Galectin-3 in Renal Neoplasms: A Diagnostic, Possible Prognostic Marker

    by Jane Y. Dancer, Luan D. Truong, Qihui Zhai, Steven S. Shen

    Context.: Galectin-3, a member of the lectin family, was shown to be expressed in normal distal tubular cells and in renal cell carcinomas (RCC). However, its diagnostic and prognostic significance in RCC is as yet undefined. Objectives.: To describe the expression of Galectin-3 among different histologic subtypes of renal neoplasms and to determine their diagnostic and prognostic significances. Design.: The expression of Galectin-3 was evaluated in 217 renal neoplasms by tissue microarray and immunohistochemistry with semiquantitative analysis. Results.: Strong expression of Galectin-3 was observed in 92 of 217 of renal neoplasms (42.4%). Although 22 of 23 oncocytomas (95.7%) and 19 of 21 chromophobe RCCs (90.5%) express Galectin-3, only 4 of 32 papillary RCCs (12.5%) and 47 of 137 clear cell RCCs (34.3%) express Galectin-3, suggesting that it may be used as a potential diagnostic marker. Galectin-3 expression was seen in 55% of high-grade (Fuhrman nuclear grades 3 and 4) versus 21% low-grade (grades 1 and 2) clear cell RCCs ( P < .001). Conclusions.: This study confirms that Galactin-3 is strongly overexpressed in renal cell neoplasms of distal tubular differentiation, that is, oncocytoma and chromophobe RCCs, suggesting it might be used as a possible differential diagnostic tool for renal cell neoplasm with oncocytic or granular cells. Furthermore, we observed a strong association of overexpression of Galectin-3 and high nuclear grade in clear cell RCC. These results also suggest a possible pivotal role for Galectin-3 in the differentiation and prognosis of clear cell RCC.


  • Number of lymph nodes examined and associated clinicopathologic factors in colorectal carcinoma.

    by Steven S Shen, Bisong X Haupt, Jae Y Ro, Jijiang Zhu, H Randoph Bailey, Mary R Schwartz

    Nodal metastasis is one of the most important prognostic factors in colorectal carcinoma. The number of lymph nodes recovered and examined in resection specimens has been recently shown to be critical for proper staging and is associated with survival. To assess the clinicopathologic factors that may be associated with the number of lymph nodes harvested from surgical resections. Clinicopathologic factors of 434 consecutive cases of colorectal cancers treated by surgical resection from a single tertiary medical center were retrospectively reviewed and correlated with number of lymph nodes recovered. Our data show that patient age, tumor location, and length of resected bowel segment were associated with number of lymph nodes harvested in surgical resections of colorectal cancer. The average number of lymph nodes was 18.2 and 17.8 for patients younger than 50 years and aged 50 through 60 years, respectively, whereas it was 14.4, 15.1, and 14.9 for patients aged 61 through 70 years, 71 through 80 years, and 80 years and older, respectively. More lymph nodes were present in resection specimens of cecum/ascending colon and descending colon cancers than in those of transverse colon, sigmoid colon, and rectal cancers. There was a linear increase in number of lymph nodes examined with increasing length of bowel resection specimens. In multivariate regression analysis, the factors that remained independent predictors of removal of 12 or more lymph nodes from resection specimens were tumor location and length of resected bowel segment. The number of lymph nodes obtained in resection specimens for colorectal cancer was significantly associated with the length of resected segments of bowel, patient age, and location of the tumor.


  • Open Access

    Number of Lymph Nodes Examined and Associated Clinicopathologic Factors in Colorectal Carcinoma

    by Steven S. Shen, Bisong X. Haupt, Jae Y. Ro, Jijiang Zhu, H. Randoph Bailey, Mary R. Schwartz

    Context. —Nodal metastasis is one of the most important prognostic factors in colorectal carcinoma. The number of lymph nodes recovered and examined in resection specimens has been recently shown to be critical for proper staging and is associated with survival. Objective. —To assess the clinicopathologic factors that may be associated with the number of lymph nodes harvested from surgical resections. Design. —Clinicopathologic factors of 434 consecutive cases of colorectal cancers treated by surgical resection from a single tertiary medical center were retrospectively reviewed and correlated with number of lymph nodes recovered. Results. —Our data show that patient age, tumor location, and length of resected bowel segment were associated with number of lymph nodes harvested in surgical resections of colorectal cancer. The average number of lymph nodes was 18.2 and 17.8 for patients younger than 50 years and aged 50 through 60 years, respectively, whereas it was 14.4, 15.1, and 14.9 for patients aged 61 through 70 years, 71 through 80 years, and 80 years and older, respectively. More lymph nodes were present in resection specimens of cecum/ascending colon and descending colon cancers than in those of transverse colon, sigmoid colon, and rectal cancers. There was a linear increase in number of lymph nodes examined with increasing length of bowel resection specimens. In multivariate regression analysis, the factors that remained independent predictors of removal of 12 or more lymph nodes from resection specimens were tumor location and length of resected bowel segment. Conclusions. —The number of lymph nodes obtained in resection specimens for colorectal cancer was significantly associated with the length of resected segments of bowel, patient age, and location of the tumor.


    • 30 January 2009
      • Vol. 2  (5) , 489-93

    Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients.

    by Jae Hee Suh, Tina Oak, Jae Y Ro, Luan D Truong, Alberto G Ayala, Steven S Shen

    To evaluate the clinicopathologic features of renal cell carcinoma in younger adults (40 years). The tumor size of the young adult group were smaller (5.3 vs 5.9 cm) and presented at less advanced stages (T3/T4 tumors, 18% vs 31%) than those occurring in the older age group (>40 years of age). The incidences of chromophobe RCC (12% vs. 6%) and of collecting duct carcinoma (5% vs 0.5%) were higher in the young adult group. The rate of nodal or distant metastasis was lower in young adult group (5% vs. 8.3%). More patients underwent partial nephrectomy in younger than older age group (30% vs 19%). There was no overall survival difference at 5 years (77% vs 70%), but there was a trend for a favorable survival in young adults at 10 years (77% vs 52%). In conclusion, RCC are relatively infrequent in patients who are younger than 40 years. The tumors in this group appear to be smaller and less advanced at presentation. Chromophobe RCC and collecting duct carcinoma are more frequently seen. More patients undergo partial nephrectomy and overall long term survival appears to be more favorable.